Table 2.

Nanoparticles functionalized with monoclonal antibodies (mAbs) targeting aberrant cancer-associated glycans. Abbreviations: poly lactic-co-glycolic acid (PLGA); gadolinium (Gd); gemcitabine (GEM); prussian blue nanoparticles (PBNPs); sorafenib (SFB); glypican-3 (GPC-3).

Antibody	Target	Cancer Type	Nanoparticles	Application	Reference
hu14.18K322A mAb	GD2	neuroblastoma	iron-oxide NPs	Targeting Diagnosis	[71]
mAb 3F8	GD2	neuroblastoma	SN-38 loaded polymeric NPs	Targeting Therapy	[72]
ch14.18/CHO	GD2	glioblastoma	PLGA nanoparticles	Targeting Therapy	[77]
hu14.18K322A	GD2	neuroblastoma and melanoma cancers	AuNPs	Targeting Diagnosis Therapy	[78]
GPC-1 mAb	GPC-1	pancreatic cancer	Gd-Au nanoclusters	Targeting Diagnosis	[76]
GPC-1 mAb	GPC-1	pancreatic cancer	GEM-loaded multifunctional Au nanocarrier	Targeting Diagnosis Therapy	[79]
GPC-3 mAb	GPC-3	hepatocellular carcinoma	PBNPs	Targeting Diagnosis Therapy	[80]
GPC-3 mAb	GPC-3	hepatocellular carcinoma	SFB-loaded polymeric NPs	Targeting Therapy	[81]